# HCA Healthcare Inc. (HCA)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/HCA/primer

## Business Model

---
ticker: HCA
step: 01
generated: 2026-05-12
source: quick-research
---

### HCA Healthcare, Inc. (HCA) — Business Overview

#### Business Description
HCA Healthcare is the largest for-profit healthcare provider in the United States — operates 190 hospitals + ~2,500 ambulatory sites of care (surgery centers, freestanding ERs, urgent care, physician clinics) in 19 states + United Kingdom. Captures ~5% of total US hospital admissions. Hub-and-spoke operating model links acute-care hospitals with outpatient centers to capture patients across the entire care continuum.

#### Revenue Model
~$75.6B FY2025 revenue from hospital-based services + outpatient services (now 42% of patient revenue). Payer mix FY2025: Managed Care + Private Insurance ~48%, Medicare ~32%, Medicaid ~10%, Self-Pay + International ~10%. Revenue per admission rises with patient acuity (case mix). Scale + payer-negotiation leverage = best-in-class economics among hospital systems.

#### Products & Services
- **190 Acute Care Hospitals** — Cardiac, oncology, neurosciences, orthopedic, emergency, women's services
- **~125 Freestanding Outpatient Surgery Centers** — Lower-cost surgical settings
- **Freestanding ERs + Urgent Care Centers** — Capture entry-point patient acquisition
- **Physician Clinics** — Primary + specialist physician network
- **Sarah Cannon Cancer Network** — Multi-state oncology platform
- **HealthONE** — Major Denver-area health system
- **MD Now Urgent Care** — Florida urgent care platform
- **HCA International** — UK operations (London Bridge Hospital, etc.)

#### Customer Base & Go-to-Market
~38M patient encounters annually. Concentrated in growth markets: Texas, Florida (largest), Tennessee, Virginia, Nevada, Colorado, Indiana. Geographic concentration in high-growth Sun Belt states + UK. Diversified payer mix protects from single-payer concentration risk.

#### Competitive Position
#1 US for-profit hospital operator by revenue + size. Competes with Tenet Healthcare (THC), Universal Health Services (UHS), Community Health Systems (CYH), HCA Florida vs nonprofits AdventHealth, Baptist, Memorial. Differentiation: scale + hub-and-spoke + data analytics + capital investment in growth corridors + acuity mix shift.

#### Key Facts
- Founded: 1968
- Headquarters: Nashville, TN
- Employees: ~280,000 (caregivers + physicians + staff)
- Exchange: NYSE (HCA)
- Sector / Industry: Healthcare / Healthcare Facilities (Hospitals)
- Market Cap: ~$110-120B
- CEO: Sam Hazen (since 2019)

## Financial Snapshot

---
ticker: HCA
step: 04
generated: 2026-05-12
source: quick-research
---

### HCA Healthcare, Inc. (HCA) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2022 | FY2023 | FY2024 | FY2025 | YoY (25) |
|--------|--------|--------|--------|--------|----------|
| Revenue | $60.2B | $64.97B | $70.6B | $75.6B | +7.1% |
| Same-Facility Admissions Growth | -2.0% | +3.6% | +5.5% | +2.4% | |
| Adj EBITDA | $12.2B | $12.65B | $13.88B | $15.57B | +12.1% |
| EBITDA Margin | 20.3% | 19.5% | 19.7% | 20.6% | +90bps |
| Net Income | $5.64B | $5.24B | $5.76B | $6.78B | +18% |
| Diluted EPS | $19.20 | $19.65 | $22.00 | $28.33 | +29% |

FY25: Same-facility admissions +2.4% in Q4; full-year inpatient + outpatient surgery + ER visits all positive. Adj EBITDA +12%; EBITDA margin 20.6% (record high). EPS +29% (driven by share buybacks compounding effect).

#### Cash Flow & Balance Sheet (FY2024)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$11.5B |
| Free Cash Flow | ~$6.5B |
| Capex | ~$5.2B (record investment) |
| Cash & Equivalents | ~$1.0B |
| Total Debt | ~$42B |
| Net Debt/EBITDA | ~2.7x |
| Buybacks | $10B authorized (early 2026) |

#### Key Ratios (approximate)
- P/E: ~16x | EV/EBITDA: ~9-10x | FCF Yield: ~5.5%
- Revenue Growth (TTM): ~7% | Op Margin: ~15%
- Dividend Yield: ~1.0% | Modest dividend; capital return primarily via buybacks
- Aggressive buybacks: ~$8-10B annually = ~7-8% share count reduction

#### Growth Profile
Long-term: 5-7% revenue growth (admissions + price/acuity) + 100bps margin expansion + 10-12% adj EBITDA growth + 12-15% EPS growth (with aggressive buybacks). $5.2B capex plan adds 600-700 beds annually + ORs + ASCs. Hub-and-spoke + AI/analytics = $400M resiliency program savings.

#### Forward Estimates
- **FY 2026**: Revenue ~$80B; adj EBITDA $16-17B; adj EPS $29.10-31.50 (raised guidance)
- ACA + Medicaid headwind: $600-900M EBITDA hit (manageable)
- **FY 2027**: Adj EPS ~$33-36 with full-year 2026 buybacks compounding
- $10B buyback authorization (Jan 2026) for 2026-27 execution

## Recent Catalysts

---
ticker: HCA
step: 12
generated: 2026-05-12
source: quick-research
---

### HCA Healthcare, Inc. (HCA) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Bullish 2026 guidance + $10B buyback authorization** — HCA raised 2026 EPS guidance to $29.10-31.50 (above $29.46 analyst average), anchored to $400M cost-savings resiliency program (AI + analytics + shared services). Authorized $10B buyback (Jan 2026) = ~8% of market cap. Buyback compounding drives 12-15% EPS growth over base 5-7% revenue growth. 2025 EPS +29% YoY.

2. **Volume + acuity tailwinds — record inpatient occupancy** — Same-facility admissions +2.4% in Q4 2025 (+5.5% in 2024). Outpatient surgery + ER visits also growing. Inpatient occupancy at all-time high. HCA expanding capacity: 600-700 beds/year + new ORs + 125 ASCs. Hub-and-spoke model captures full continuum of patient care. Sun Belt geographic exposure (Texas, Florida) = demographic tailwind.

3. **20.6% EBITDA margin record + scale advantages** — FY25 adj EBITDA margin reached record 20.6% (+90bps YoY). Scale advantages: bulk purchasing, payer negotiating power, data analytics + AI, shared services. Best-in-class hospital operator metrics vs Tenet, UHS, Community Health. Resiliency program: $400M cost savings program in 2026.

4. **190 hospitals + 2,500 ambulatory sites = irreplaceable footprint** — Largest US for-profit hospital network + ambulatory presence. Captures ~5% of total US hospital admissions. Geographic concentration in growth Sun Belt states. Building new facilities is extraordinarily difficult (capital + regulatory + labor) = HCA's footprint is a multi-decade competitive moat.

#### Bear Case Risks

1. **ACA exchange subsidies + Medicaid reform = $1B+ EBITDA hit** — CFO Mike Hart guided $600-900M EBITDA hit in 2026 from health insurance exchange dynamics (premium tax credit expiration). Plus $250-450M net benefit decline from Medicaid state supplemental payment program changes. Combined could exceed $1B. Bear case $425 target assumes ACA breach + resiliency underdelivery + Florida grandfathering rejection.

2. **Trump healthcare policy uncertainty (Medicaid expansion + ACA)** — Trump 47 + GOP Congress could further reduce Medicaid + ACA funding in 2026-27. If federal Medicaid expansion repealed or capped, HCA payor mix deteriorates. Inflation Reduction Act drug pricing + 340B reforms also relevant. Hospital industry sees 2026 as a "make-or-break" year per Axios.

3. **Inflation + tariff impact on medical supplies** — Medical supplies + devices facing inflation. New 2026 tariff regime (Section 232 + reciprocal) could increase imported supply costs. HCA mitigating via supply base diversification + contract pricing, but ongoing margin pressure. Labor inflation also persistent.

4. **Premium valuation + leveraged balance sheet** — Net debt/EBITDA ~2.7x is elevated post buyback financing. P/E ~16x is below peers but not cheap given policy headwinds. Stock has gone -8.5% on policy news. Capital return capacity could compress if EBITDA disappoints.

#### Upcoming Events

- **Q2 2026 earnings (July 2026)** — ACA enrollment dynamics + resiliency program execution
- **Q3 2026 earnings (October 2026)** — Mid-year guide reset + CMS state program decisions
- **CMS state Medicaid program decisions** — Direct EBITDA impact
- **Open Enrollment 2027 (Oct-Nov 2026)** — Exchange volume signal
- **AHA + hospital industry policy advocacy** — Federal Medicaid reform outcomes

#### Analyst Sentiment

Sell-side consensus is **Buy** with 13 of 25 analysts rating Buy + 2 Outperform vs 9 Hold + 1 Sell. Mean price target $543 (15.1% upside from ~$472). Bulls cite scale moat + volume growth + 20.6% EBITDA margin + $10B buyback + Sun Belt demographics. Bears focus on ACA/Medicaid headwinds + Trump policy + tariff cost. HCA is widely viewed as the highest-quality public hospital operator with cyclical policy headwinds.

#### Research Date
Generated: 2026-05-12

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/hca
- Full research API: GET /api/v1/research/HCA/memo
- Coverage universe: /stocks